Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2005-12-20
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S120000, C546S119000, C544S127000, C544S362000, C514S234200, C514S253030
Reexamination Certificate
active
06977262
ABSTRACT:
The present invention provides dihydropyrazolopyridine compounds represented by the formula (I):wherein each symbol is as defined in the specification, optically active forms thereof, and pharmaceutically acceptable salts thereof and hydrates thereof. The compounds of the present invention show a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3β), and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications and neurodegenerative diseases or as immunopotentiators.
REFERENCES:
patent: 3790576 (1974-02-01), De Wald
patent: 0 107 619 (1984-05-01), None
patent: 0 114 273 (1984-08-01), None
patent: 0 157 260 (1985-10-01), None
patent: 0 327 500 (1989-08-01), None
patent: 0 355 234 (1990-02-01), None
patent: 2 146 326 (1985-04-01), None
patent: 92 03137 (1992-03-01), None
patent: 99 65897 (1999-12-01), None
patent: 01 66544 (2001-09-01), None
patent: 01 81345 (2001-11-01), None
Jairo Quiroga et al., entitled “Synthesis of 5-cyano-4, dihydropyrazolo'3,4-bl pyridin-4-ones . . .”, Database CA 'Online! Chemical Abstracts Service, Columbus, Ohio, US.
Ikuo Adachi et al., entitled “Studies on dihydropyridines. Synthesis of 4, 7-dihydropyrazolo'3,4-bipridines with vasodilating and antihypertensive activities”, Chemical and Pharmaceutical Bulletin., vol. 35, No. 8, pp. 3235-3252.
Reinhard Troschuetz, entitled “Synthesis of pyrido′2,3-dipryrimidines with a trimethoprim partial structure”, Database CA 'Online! Chemical Abstracts Service, Columbus, Ohio, US.
F. Attaby, entitled “Reactions with cyanothioacetamide derivatives: synthesis of several new pyridine and annulated pyridine derivatives”, Database Caplus ′Online! Chemical Abstracts Service, Columbus, Ohio, US.
Dyachenko et al., entitled “Synthesis and properties of N-methylmorpholinium-6-amino-3,5-dicyano-1,4-dihydropyridine-4-spirocyclopentane-2-thiolate”, Database Caplus ′Online! Chemical Abstracts Service, Columbus, Ohio, US.
Jairo Quiroga et al., entitled “Synthesis and structural analysis of 5-cyanodihydropyrazolo′3,4- bipyridines”, Journal of Heterocyclic Chemistry (2001).
J. Quiroga et al., entitled “Regioselective synthesis of 4,7,8,9-tetrahydro-2H-pyrazolo′3,4-biquinolin-5(6H)-ones. Mechanism and structural analysis”. Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 57, No. 32, Aug. 6, 2001.
M. Hoshi et al., “Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3β in brain”, Proc. Natl. Acad. Sci., vol. 93, pp. 2719-2723, 1996.
S. R. D'Mello et al., “Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons”, Experimental Cell Research, No. 211, pp. 332-338, 1994.
C. Volonte et al., Neurosci. Letters, vol. 172, pp. 6-10, 1994.
S. Nonaka et al., “Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats”, NeuroReport, vol. 9, No. 9, pp. 2081-2084, 1998.
S. B. Maggirwar et al., “HIV-1 Tat-Mediated activation of glycogen synthase kinase-3β contributes to Tat-mediated neurotoxicity”, Journal of Neurochemistry, vol. 73, No. 2, pp. 578-586, 1999.
V. Stambolic et al., “Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells”, Current Biology, vol. 6. No. 12, pp. 1664-1668, 1996.
P. S. Klein et al., “A molecular mechanism for the effect of lithium on development”, Proc. Natl. Acad. Sci., vol. 93, pp. 8455-8459, 1996.
G. Chen et al., “The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3”, Journal of Neurochemistry, vol. 72, pp. 1327-1330, 1999.
S. Nonaka et al., “Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx”, Proc. Natl. Acad. Sci., vol. 95, pp. 2642-2647, 1998.
C. R. Beals et al., “Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3”, Science, vol. 275, pp. 1930-1933, 1997.
I. A. Graef et al., “L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons”, Letters to Nature, vol. 401, pp. 703-708, 1999.
A. J. Zhu et al., “β-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion”, Development, vol. 126, pp. 2285-2298, 1999.
S. T. Davis et al., “Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors”, Science, vol. 291, pp. 134-137, 2001.
T. T. Lee et al., “Overexpression of cellular activity and protein level of protein kinase F /GSK-3β correlates with human thyroid tumor cell dedifferentiation”, Journal of Cellular Biochemistry, vol. 58, pp. 474-480, 1995.
K. P. Hoeflich et al., “Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation”, Nature, vol. 406, pp. 86-90, 2000.
S. A. Milligan et al., “Inhibition of NF-kB with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro”, Anticancer Research, vol. 21, pp. 39-44, 2001.
R. Romieu-Mourez et al., “Roles of IKK kinase and protein kinase CK2 in activation of nuclear factor-kB in breast cancer”, Cancer Research, vol. 61, pp. 3810-3818, 2001.
S. E. Nikoulina et al., “Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes”, Diabetes, vol. 49, pp. 263-271, 2000.
R. V. Bhat et al., “Regulation and localization of tyrosine218phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration”, Proc. Natl. Acad. Sci., vol. 97, pp. 11074-11079, 2000.
Fujimura Masatake
Fukunaga Kenji
Hanano Tokushi
Kohara Toshiyuki
Okabe Hirotaka
Aulakh Charanjit S.
Mitsubishi Pharma Corporation
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Dihydropyrazolopyridine compounds and pharmaceutical use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyrazolopyridine compounds and pharmaceutical use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyrazolopyridine compounds and pharmaceutical use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497710